SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is surging following a positive clinical update that highlights an annual recurrence rate of less than 1% in the open-label arm of its Phase III trial, fueling community optimism about the company's competitive position. Investors are actively discussing the trial's statistically significant results compared to industry standards, the high level of insider ownership, and growing anticipation for upcoming abstract presentations.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending as the community debates the geopolitical fallout of the ongoing conflict in the Middle East, specifically focusing on the closure of the Strait of Hormuz and the administration's call for international naval support. Investors are actively discussing the potential impact of these tensions on global energy prices, the effectiveness of proposed trade tariffs, and broader concerns regarding market stability as the administration navigates a complex coalition-building process.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is seeing significant investor attention following a strategic partnership with Tesla that provides insurance discounts for FSD-enabled vehicles, fueling community speculation about data-driven growth. While the stock has experienced notable volatility and high short interest, bulls are focused on the company's AI-native insurance platform and its potential to scale rapidly against traditional carriers.

What is DAG? In more traditional blockchains, the host provides the food/drinks (i.e resources) for this party. And when the guests arrive, the amount of resources can only accommodate so many people, the portions are small and then everything eventually runs out and the party ends. Think Constellation DAG like a potluck (a party where everyone brings food/drinks). With every added guest (node to the network), the more resources the party has to keep going. This is the nature of Constellation, a distributed system that scales horizontally.  Is Constellation a Blockchain? Not exactly. Although inspired by the principles of decentralization, many standard blockchains such as Bitcoin and Ethereum face scalability issues. This is why the next, generation of decentralized networks such as Hashgraph, IOTA, and Constellation have turned to DAG.  What is a Microservice? “Microservices” is an approach to application development in which a large application is built as a suite of modular services. Each module supports a specific business goal and uses a simple, well-defined interface to communicate with other sets of services. Uber, for example, is not a singular app purse. It is a unified app which means it is a single interface that brings together their driver app, their rider app, and their corporate team app.

Constellation

Constellation (DAG) is trending as investors focus on its potential as a specialized data-validation layer, particularly through its recent merger agreement with AI holding company AIAI and its history of contracts with U.S. government and defense agencies. The community is actively weighing the long-term utility of the Hypergraph architecture against the risks of a slow retail rollout, with many highlighting potential enterprise integration with major cloud providers as the primary catalyst for future growth.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing intense market activity as investors position themselves for a series of high-stakes catalysts, including an imminent U.S. patent approval and a PDUFA decision for its ADHD treatment in late May. The community is actively discussing the stock's low float and the potential for a significant run, drawing parallels to its previous price action and highlighting strong institutional interest.

Tencent Music Entertainment Group engages in the business of operating online music entertainment platforms to provide music streaming, online karaoke, and live streaming services. Its product brands include QQ Music, Kugou Music, Kuwo Music, and WeSing. The company was founded on June 6, 2012 and is headquartered in Shenzhen, China.

Tencent Music Entertainment Group - ADR

Tencent Music Entertainment Group

Tencent Music Entertainment Group (TME) is seeing increased investor attention as market sentiment shifts following favorable financial results and sustained earnings growth. The stock is currently trending due to active discussions regarding its strong valuation compared to international streaming peers, persistent share buyback programs, and strategic focus on monetizing its user base through subscription services.

Atour Lifestyle Holdings Ltd. engages in the development of lifestyle brands around hotel. Its brands includes: Atour Hotel, Atour S, Atour Light, Atour X Hotel, ZHOTEL and A.T. House. The company was founded by Hai Jun Wang on April 10, 2012 and is headquartered in Shanghai, China.

Atour Lifestyle Holdings Ltd - ADR

Atour Lifestyle Holdings is surging on optimism surrounding China's easing of COVID-19 restrictions, fueling investor excitement around its hospitality network expansion and retail product growth. The community is buzzing with speculation about potential short-term volatility, with many traders closely monitoring volume spikes and technical breakout patterns as the stock gains traction as a momentum play.

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Tandem Diabetes Care Inc

Tandem Diabetes is currently trending as investors react to a significant revenue beat and reaffirmed full-year sales guidance, with community sentiment shifting between optimistic growth potential and concerns over competitive pressure. Many traders are actively monitoring the stock's recent volatility and potential as a long-term acquisition target, while others debate the impact of new technology launches on its market share.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

The XRP community is currently polarized as the Bitwise XRP ETF launch drives intense debate over its role in institutional adoption versus speculative price manipulation. Traders remain divided between those aggressively buying into the current price volatility and others expressing deep skepticism about the asset's long-term utility and historical price action.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is seeing high volatility following the GTC keynote, where CEO Jensen Huang revealed a $1 trillion revenue outlook for its Blackwell and Vera Rubin platforms through 2027. Despite the massive long-term demand visibility and new partnerships with Uber and global automakers, the stock is experiencing significant intraday price swings as retail call buyers and institutional market makers navigate the high volume of options activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Under the new rule, Hospital Outpatient Department (HOPD) reimbursement for Nyxoah’s Genio hypoglossal nerve stimulation implants will increase to approximately $45,000 starting in 2026.</li><li>According to Nyxoah, the Genio procedure is well-suited for the ASC environment, and the new rules create new opportunities for site-of-service diversification as well.</li></ul>Shares of Nyxoah SA (NYXH) jumped 7% in the pre-market session on Wednesday after the company said that its Genio Therapy would benefit from the new medicare reimbursement criteria for CY2026.The U.S. Centers for Medicare &amp; Medicaid Services (CMS) finalized its CY2026 medicare reimbursement rules on Friday.<h2 class="st-heading-2">How Will It Aid Nyxoah?</h2>Under the new rule, Hospital Outpatient Department (HOPD) reimbursement for Nyxoah’s Genio hypoglossal nerve stimulation implants for the treatment of Obstructive Sleep Apnea will increase to approximately $45,000 starting in 2026, a 48% rise compared to 2025, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/26/3194857/0/en/Nyxoah-s-Genio-Therapy-Receives-Significant-2026-Medicare-Reimbursement-Increases-Under-Final-CMS-Rule.html">said</a>. Ambulatory Surgery Centers (ASC) facility reimbursement, meanwhile, will increase to $42,373, reflecting a 58% increase compared to 2025.Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions. Further, the procedure is well-suited for the ASC environment, and the change in rules creates new opportunities for therapy expansion and site-of-service diversification, the company added.<h2 class="st-heading-2">Others To Benefit From New Rules</h2>The new rules apply to Nyxoah’s peers, too. Earlier this week, Stifel analyst Jonathan Block upgraded Inspire Medical Systems (INSP) to ‘Buy’ from ‘Hold’ while also hiking the price target to $110, up from $100.Inspire Medical makes the Inspire V implant to treat obstructive sleep apnea. It is installed in an approximate 60-minute outpatient procedure. According to the Stifel analyst, the company's headwinds are easing following CMS's positive reimbursement revision on Friday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NYXH fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:624/60;" src="data:image/png;base64,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" width="624" height="60" alt="NYXH’s Sentiment Meter and Message Volume as of 7:56 a.m. ET on Nov. 26, 2025 | Source: Stocktwits"><figcaption>NYXH’s Sentiment Meter and Message Volume as of 7:56 a.m. ET on Nov. 26, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NYXH">NYXH stock</a> fell 43% this year and by about 44% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/bytedance-reportedly-tops-chinese-nvidia-chip-buyers-but-now-it-can-t-use-them/cL53FkSREWe">Bytedance Reportedly Tops Chinese Nvidia Chip Buyers – But Now It Can't Use Them</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Natalie Boller, 63, has a Genio Nyxoah bilateral hypoglossal nerve stimulator implant fitted for obstructive sleep apnoea. Picture date: Wednesday December 4, 2024. (Photo by Lucy North/PA Images via Getty Images)

Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy

Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions.

Equity

<ul class="summary-bullets"><li>Aucatzyl will be available through routine commissioning by the NHS, the company said.</li><li>Aucatzyl was approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024.</li><li>The company also intends to launch Aucatzyl in England and Wales soon, It added.</li></ul> Autolus Therapeutics Plc (AUTL) said on Tuesday that the UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending its Aucatzyl CAR T cell therapy for use in the National Health Service (NHS) in England and WalesShares of the company rose 14% in the premarket session at the time of writing.<h2 class="st-heading-2">UK Approval And Recommendation</h2>NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/nice-recommends-aucatzylr-obecabtagene-autoleucel-treatment">said</a>. Relapsed or refractory B-cell precursor acute lymphoblastic leukemia is a cancer that either returns after treatment or never responded to initial therapy.Aucatzyl will be available through routine commissioning by the NHS, the company said. The company also intends to launch Aucatzyl in England and Wales soon, it added.Aucatzyl or obecabtagene autoleucel is an autologous CD19 CAR T cell therapy. Autologous CD19 CAR T-cell therapy is an immunotherapy that uses a patient's own T-cells, which are genetically modified to target and attack cells that express the CD19 protein. This treatment has shown high efficacy in relapsed or refractory B-cell malignancies.The U.S. Food and Drug Administration approved Aucatzyl for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in November 2024. A conditional marketing authorization from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) followed in April 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AUTL stayed within the ‘bearish’ territory over the past 24 hours, while message volume jumped from ‘low’ to ‘normal’ levels.A Stocktwits user sees the stock hitting as high as $2.50.<stembedurl>https://stocktwits.com/nader_1/message/637361441</stembedurl>Another applauded the recent announcement and expressed hope that cell therapy would become the standard of care.<stembedurl>https://stocktwits.com/janed102/message/637360741</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by 47% this year and by about 58% over the past 12 months. &nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-keys-stock-surge-14-in-premarket-today/cL52hzFREX8">Why Did KEYS Stock Surge 14% In Premarket Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK

NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said. 

Nasdaq-listed shares of Nyxoah SA (NYXH) soared 13% on Monday morning after the company announced that the first U.S commercial patients with Obstructive Sleep Apnea (OSA) have been successfully implanted with its Genio system.OSA is a common sleep disorder where the upper airway repeatedly collapses during sleep, leading to breathing pauses. It is associated with increased mortality risk and comorbidities, including cardiovascular diseases, depression, and stroke.Nyxoah’s Genio therapy is a mask-free treatment option and works by gently stimulating hypoglossal nerves to contract muscles on both sides of the tongue, keeping the airway open throughout the night. The Genio System features a battery-free stimulator that’s externally powered by a sleep wearable, with customizable settings. It provides an alternative to CPAP therapy, which uses a machine to deliver pressurized air through a mask, keeping the airway open during sleep and preventing breathing pauses.Nyxoah CEO Olivier Taelman said that the company has also trained surgeons, obtained Value Analysis Committee (VAC) approvals, and achieved successful coverage from major payors.“What's also particularly encouraging is the strong demand we're seeing from physicians, with surgeons actively reaching out for training opportunities, many of whom already have patients lined up for implants,” he <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.nyxoah.com/press-releases">added</a>.The Genio system received approval from the U.S. Food and Drug Administration in August for a subset of patients with moderate to severe OSA. The approval was supported by a trial that demonstrated Genioi’s efficacy regardless of a patient's sleeping position.<a href="https://stocktwits.com/symbol/NYXH">NYXH stock</a> is down by 30% this year and by about 40% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/adobe-expects-us-holiday-online-sales-to-reach-253-4-billion-this-year/ch6R3KNR3gh">Adobe Expects US Holiday Online Sales To Reach $253.4 Billion This Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder

Nyxoah CEO Olivier Taelman said that the company has also trained surgeons, obtained Value Analysis Committee approvals, and achieved successful coverage from major payors.

BMED
iShares Health Innovation Active ETF

Feed

News

Sentiment

Fundamentals

Info

Latest BMED News

BMEDiShares Health Innovation Active ETF